BTIG Terminates Sales Agreement With Matinas BioPharma, Effective Immediately On July 23; Incurs No Termination Penalties Or Expenses From Sales Agreement Termination
As previously disclosed, on July 2, 2020, Matinas BioPharma Holdings, Inc. (the "Company") entered into an At-The-Market Sales Agreement (the "Sales Agreement") with BTIG, LLC ("BTIG"), pursuant
Matinas BioPharma's sales deal with BTIG ended on July 23, but the company doesn't have to pay any fees for stopping it. This means the company lost a way to raise money quickly, so watch how they find cash next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.